Literature DB >> 2413885

Purification of human factor VIII:C and its characterization by Western blotting using monoclonal antibodies.

F Rotblat, D P O'Brien, F J O'Brien, A H Goodall, E G Tuddenham.   

Abstract

Human factor VIII:C has been purified over 300 000-fold from cryoprecipitate by polyelectrolyte purification followed by affinity chromatography on Sepharose linked to antibody to factor VIIIR:Ag (monoclonal or polyclonal) and Sepharose linked to monoclonal antibody to factor VIII:C. The purified material has been analyzed by polyacrylamide gel electrophoresis (PAGE) and Western blotting using monoclonal antibodies. PAGE shows predominant bands at 360K (unreduced), 210K, and 90K and an 80K/79K doublet; Western blotting showed all the monoclonal antibodies used bound the 360K form. In a small-scale purification, plasma from blood taken directly into thrombin inhibitor Kabi S-2581 was applied directly to the monoclonal anti-factor VIII:C column. Western blot analysis of this material showed the 360K band on reduction. The purified factor VIII:C could be activated 13-fold by human thrombin. Gel analysis of the activated material showed intensification followed by fading of the band at 90K and generation of bands at 70K/69K, 55K, and 40K. Western blotting shows that the 70K/69K doublet derives from the 80K/79K moiety and the 40K peptide derives from the 90K and is presumed to contain the active site. From these studies an epitope map of the factor VIII:C molecule has been constructed.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2413885     DOI: 10.1021/bi00337a007

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  18 in total

1.  Monoclonal antibodies to human factor VII: production of immunodepleted plasma for VII:C assays.

Authors:  T Takase; E G Tuddenham; S Chand; A H Goodall
Journal:  J Clin Pathol       Date:  1988-03       Impact factor: 3.411

Review 2.  Insight into the structure, function, and biosynthesis of factor VIII through recombinant DNA technology.

Authors:  R J Kaufman
Journal:  Ann Hematol       Date:  1991-09       Impact factor: 3.673

3.  Structural and functional characterization of Factor VIII-delta II, a new recombinant Factor VIII lacking most of the B-domain.

Authors:  N Bihoreau; P Paolantonacci; C Bardelle; M P Fontaine-Aupart; S Krishnan; J Yon; J L Romet-Lemonne
Journal:  Biochem J       Date:  1991-07-01       Impact factor: 3.857

4.  Localization of a factor VIII-inhibiting antibody epitope to a region between residues 338 and 362 of factor VIII heavy chain.

Authors:  J Ware; J R Toomey; D W Stafford
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

5.  Molecular basis of factor VIII inhibition by human antibodies. Antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid.

Authors:  M Arai; D Scandella; L W Hoyer
Journal:  J Clin Invest       Date:  1989-06       Impact factor: 14.808

6.  Structural model of porcine factor VIII and factor VIIIa molecules based on scanning transmission electron microscope (STEM) images and STEM mass analysis.

Authors:  M W Mosesson; D N Fass; P Lollar; J P DiOrio; C G Parker; G J Knutson; J F Hainfeld; J S Wall
Journal:  J Clin Invest       Date:  1990-06       Impact factor: 14.808

7.  Isolation and characterization of human factor VIII: molecular forms in commercial factor VIII concentrate, cryoprecipitate, and plasma.

Authors:  L O Andersson; N Forsman; K Huang; K Larsen; A Lundin; B Pavlu; H Sandberg; K Sewerin; J Smart
Journal:  Proc Natl Acad Sci U S A       Date:  1986-05       Impact factor: 11.205

8.  Factor VIII-East Hartford (arginine 1689 to cysteine) has procoagulant activity when separated from von Willebrand factor.

Authors:  A M Aly; L W Hoyer
Journal:  J Clin Invest       Date:  1992-05       Impact factor: 14.808

9.  Endothelial cell processing and alternatively spliced transcripts of factor VIII: potential implications for coagulation cascades and pulmonary hypertension.

Authors:  Claire L Shovlin; Gillian Angus; Richard A Manning; Grace N Okoli; Fatima S Govani; Kay Elderfield; Graeme M Birdsey; Inês G Mollet; Michael A Laffan; Francesco A Mauri
Journal:  PLoS One       Date:  2010-02-11       Impact factor: 3.240

10.  The pro-polypeptide of von Willebrand factor is required for the formation of a functional factor VIII-binding site on mature von Willebrand factor.

Authors:  A Leyte; J Voorberg; H B Van Schijndel; B Duim; H Pannekoek; J A Van Mourik
Journal:  Biochem J       Date:  1991-02-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.